跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2016-000499-83-BE
EUCTR2016-000499-83-BE进行中（未招募）1 期

A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH. - PoM in target population

SCS Boehringer Ingelheim Comm. V0 个研究点目标入组 108 人开始时间: 2017年4月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
108
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • •1. Clinical evidence of NASH defined as
  • •a. histological evidence of NASH (no more than 3 years prior to screening) OR
  • •b. clinical imaging results suggestive of NASH (no more than 3 years prior to screening) OR within the screening phase, imaging procedures performed as per local standard i. evidence of hepatic steatosis >5% measured by the MRI-PDFF or assessed as
  • •steatosis (raised echogenicity of the liver parenchyma) by ultrasound AND
  • •ii. evidence of liver fibrosis defined as mean stiffness > 3.64 kPa as measured by the MRE protocol or mean stiffness > 7.2 kPa as measured by ultrasound based transient elastography (Fibroscan®)
  • •2. Increased ALT defined as
  • •a. ALT >1.5 ULN at screening and ALT >1.25 ULN in a local lab within 1 week to 3 months prior screening
  • •b. Historic ALT >1.25 ULN more than 3 months prior to screening and two consecutive ALT >1.5x ULN must be confirmed at least 1 week apart within the screening period
  • •3. Age = 18 and =75 years at screening
  • •4. BMI =25kg/m2 and <45kg/m2
  • •5. Stable body weight defined as less than 5% change in body weight in the 3 months prior to screening while being treated with the standard of care at the study site.
  • •6. Treatment with Antidiabetic, anti-obesity concomitant medication including any insulin regimen, and vitamin E needs to be stable for 3 months prior to informed consent and expected to be stable throughout the trial. All other concomitant medication has to be stable for at least 4 weeks prior screening. Concomitant medications taken to treat acute conditions (e.g. headache, sinusitis) for a short period (< 7 days) are permissible, if not otherwise prohibited.
  • •For restricted medications please refer to section 4.2.2.1.
  • •7. For female patients:: Women of childbearing potential* can be randomized after a negative pregnancy test and under adaquate contraception with two methods, of which at least one is highly effective, during the trial.
  • •* A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
  • •8. Signed and dated written informed consent in accordance with GCP and local legislation prior to admission to the trial.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 88
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 20

排除标准

  • •1. Current or history of significant alcohol consumption (defined as intake of >210g/week in males and >140g/week females on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on investigator judgement.
  • •2. Prior participation in an interventional NASH trial 6 months before baseline or 5 times halflife of the investigational drug, whichever is longer.
  • •3. Prior or planned bariatric surgery during study conduct, except gastric-band surgery more than 2 years prior to screening (including adjustments) with a stable body weight within the last 12 months.
  • •4. Use of drugs historically associated with liver injury, hepatic steatosis or steatohepatitis in the 4 weeks prior to screening; please refert to section 4.2.2.
  • •5. History of liver cirrhosis (fibrosis stage 4) or history of other forms of chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease, hemochromatosis, A1At deficiency, history of liver transplantation).
  • •6. History of HIV.
  • •7. Solid liver lesions other than haemangiomas. a. Suspicion or diagnosis or history of hepatocellular carcinoma (HCC)
  • •8. eGFR <60ml/min/1.73m2 at screening (CKD-EPI formula).
  • •9. ALT >5.0 ULN at screening.
  • •10. Platelet count < 150.000/µL
  • •11. Bilirubin level > ULN (except for known Gilbert´s disease with a conjugated bilirubin of < 0.3 mg/dL))
  • •12. Uncontrolled diabetes defined as an HbA1c =9.5% in the 3 months prior to or at screening.
  • •13. Diagnosis of a serious or unstable disease including hepatic (other than NASH), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic , psychiatric, immunologic, or hematologic disease and other conditions that, in the clinical judgment of the investigator, are likely to interfere with the analyses of safety and efficacy in this study. Patients with an expected life expectancy of less than 2 years are also excluded.
  • •14. Major surgery (major according to the investigator’s assessment) performed within 12 weeks prior to randomisation or planned during study conduct, e.g. hip replacement.
  • •15. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  • •16. Patients who must or wish to continue the intake of restricted medications (see section 4.2.2.1) or any drug considered likely to interfere with the safe conduct of the trial.
  • •17. Previous randomisation in this trial.
  • •18. Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).
  • •19. Chronic drug abuse or any condition that, in the investigator’s opinion, makes them an unreliable study subject or unlikely to complete the trial.
  • •20. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • •21. Patients with Wolff-Parkinson-White Syndrom

研究者

发起方
SCS Boehringer Ingelheim Comm. V

相似试验

进行中（未招募）
不适用
A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week treatment period as add-on to 10 mg donepezil once daily in patients with mild to moderate dementia of the Alzheimer’s type.mild to moderate demetia of the Alzheimer type (DAT)MedDRA version: 7.0Level: LLTClassification code 10001896
EUCTR2004-001100-12-HUBoehringer Ingelheim Pharma GmbH & Co. KG80
已完成
2 期
A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.
NL-OMON47669Boehringer Ingelheim2
进行中（未招募）
1 期
Different doses of BI 1467335 compared to placebo in patients with clinical evidence of NASHon-alcoholic steatohepatitisMedDRA version: 20.0 Level: PT Classification code 10076331 Term: Steatohepatitis System Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2016-000499-83-IEBoehringer Ingelheim Limited108
进行中（未招募）
1 期
BI 425809 in patients with cognitive impairment due to Alzheimer's Disease.Cognitive impairment due to Alzheimer's Disease Patients with diagnosis of mild-to moderate Alzheimer’s dementia according to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease.MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders
EUCTR2015-005438-24-GBBoehringer Ingelheim Limited950
进行中（未招募）
1 期
BI 409306 in patients with cognitive impairment due to Alzheimer's DiseaseCognitive impairment due to Alzheimer's DiseaseMedDRA version: 19.1Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2013-005040-28-BESCS Boehringer Ingelheim Comm.V655